Sheryl M. Gough

Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models

Sheryl M. Gough, John J. Flanagan, Jessica L.F. Teh et al. · Clinical Cancer Research · 2024 · 120 citations · Full text

Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer

Lawrence B. Snyder, John J. Flanagan, Yimin Qian et al. · Cancer Research · 2021 · 105 citations

Breast Oncology, Estrogen Receptor, Pharmacotherapy +20

Age-related epigenetic drift in the pathogenesis of MDS and AML

Shinji Maegawa, Sheryl M. Gough, Naoko Watanabe‐Okochi et al. · Genome Research · 2014 · 86 citations · Full text

NUP98–PHF23 Is a Chromatin-Modifying Oncoprotein That Causes a Wide Array of Leukemias Sensitive to Inhibition of PHD Histone Reader Function

Sheryl M. Gough, Fan Lee, Fan Yang et al. · Cancer Discovery · 2014 · 82 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Wide Array +23

Oxidative stress leads to increased mutation frequency in a murine model of myelodysplastic syndrome

Yang Jo Chung, Carine Robert, Sheryl M. Gough et al. · Leukemia Research · 2013 · 53 citations

Hematological Malignancy, Bone Marrow Failure, Genetics +10